Advertisement

Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer

  • Monireh Davoodian
  • Nadia Boroumand
  • Mostafa Mehrabi Bahar
  • Amir Hosein Jafarian
  • Mahdi Asadi
  • Seyed Isaac HashemyEmail author
Original Article

Abstract

Breast cancer is the second leading cause of cancer death in women with increasing incidence. Hence, finding a diagnostic factor and/or potential drug target could lead to an earlier diagnosis or a more effective therapeutic protocol. It is shown that substance P (SP) through its receptor neurokinin-1 (NK1R) could initiate tumor cell proliferation, angiogenesis, and migration. This was a case–control study on 41 women with breast cancer and 34 healthy controls. Serum level of SP was measured using an ELISA method, and immunohistochemistry staining was performed to study NK1R expression in different cell compartments. Assessing serum SP values of patients showed significantly higher levels than those of healthy individuals. However, no significant correlation was found between SP levels and tumor criteria, but between SP and HER-2. Moreover, the percentage, intensity of staining as well as tissue distribution of NK1R were significantly higher in tumor tissues as compared with controls. Increased serum SP levels and NK1R tissue distribution were observed in patients with breast cancer as compared with their controls, highlighting the involvement of SP/NK1R complex in breast cancer incidence. NK1R profound expression in tumor cell cytoplasm and its significant correlation with the majority of cancer features can be of importance to be taken into consideration as a possible potential therapeutic target in future targeted therapeutic strategies. Furthermore, cytoplasmic expression of NK1R can be suggested as a potent prognostic factor as it has shown significant correlation with TNM and tumor grade.

Keywords

Breast cancer Substance P NK-1 receptor Cancer stage 

Notes

Acknowledgements

We are very grateful to all patients who participated in this study. This work was based on the Research Project No. 922072, as the Master dissertation of Monireh Davoodian, financed by the Research Council of Mashhad University of Medical Sciences.

Compliance with ethical standards

Conflict of interest

Authors declare that they do not have any conflict of interest.

References

  1. 1.
    Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW (2014) Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev 94(1):265–301CrossRefGoogle Scholar
  2. 2.
    Chang MM, Leeman SE (1970) Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J Biol Chem 245(18):4784–4790Google Scholar
  3. 3.
    Stanisz AM (2001) Neurogenic inflammation: role of substance P. In: NeuroImmune biology, vol 1. Elsevier, New York, pp 373–378CrossRefGoogle Scholar
  4. 4.
    Suvas S (2017) Role of substance P neuropeptide in inflammation, wound healing, and tissue homeostasis. J Immunol 199(5):1543–1552CrossRefGoogle Scholar
  5. 5.
    Mistrova E, Kruzliak P, Dvorakova MC (2016) Role of substance P in the cardiovascular system. Neuropeptides 58:41–51CrossRefGoogle Scholar
  6. 6.
    Mashaghi A, Marmalidou A, Tehrani M, Grace PM, Pothoulakis C, Dana R (2016) Neuropeptide substance P and the immune response. Cell Mol Life Sci 73(22):4249–4264CrossRefGoogle Scholar
  7. 7.
    Mangano A, Abbate GM, Levrini L (2015) Substance P and pain in orthodontics: a brief review. Inflamm Cell Signal 2(4):e1027Google Scholar
  8. 8.
    Saria A (1987) The role of substance P and other neuropeptides in transmission of pain. In: Pain. Springer, New York, pp 33–35CrossRefGoogle Scholar
  9. 9.
    Nowicki M, Ostalska-Nowicka D, Kondraciuk B, Miskowiak B (2006) The significance of substance P in physiological and malignant hematopoiesis. J Clin Pathol 60:749–755CrossRefGoogle Scholar
  10. 10.
    Rosso M, Munoz M, Berger M (2012) The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. Sci World J.  https://doi.org/10.1100/2012/381434 Google Scholar
  11. 11.
    Chen X-Y, Ru G-Q, Ma Y-Y, Xie J, Chen W-Y, Wang H-J, Wang S-B, Li L, Jin K-T, He X-L (2016) High expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis. OncoTargets Ther 9:3595Google Scholar
  12. 12.
    Gharaee N, Pourali L, Jafarian AH, Hashemy SI (2018) Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in endometrial cancer. Mol Biol Rep.  https://doi.org/10.1007/s11033-018-4387-1 Google Scholar
  13. 13.
    Muñoz M, Coveñas R (2014) Involvement of substance P and the NK-1 receptor in pancreatic cancer. World J Gastroenterol 20(9):2321CrossRefGoogle Scholar
  14. 14.
    Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA, Sampson JH, Kwatra MM (2009) A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J Neurochem 109(4):1079–1086CrossRefGoogle Scholar
  15. 15.
    Muñoz M, González-Ortega A, Rosso M, Robles-Frias MJ, Carranza A, Salinas-Martín MV, Coveñas R (2012) The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. Peptides 38(2):318–325CrossRefGoogle Scholar
  16. 16.
    Ping F, Shang J, Zhou J, Song J, Zhang L (2012) Activation of neurokinin-1 receptor by substance P inhibits melanogenesis in B16-F10 melanoma cells. Int J Biochem Cell Biol 44(12):2342–2348CrossRefGoogle Scholar
  17. 17.
    MUñOz M, González-Ortega A, Salinas-Martín MV, CARRANzA A, Garcia-Recio S, Almendro V, Coveñas R (2014) The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. Int J Oncol 45(4):1658–1672CrossRefGoogle Scholar
  18. 18.
    Covenas R, Munoz M (2014) Cancer progression and substance P. Histol Histopathol 29(7):881–890Google Scholar
  19. 19.
    DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A (2017) Breast cancer statistics, 2017, racial disparity in mortality by state. CA: A Cancer J Clin 67(6):439–448Google Scholar
  20. 20.
    Ahmad A (2013) Pathways to breast cancer recurrence. ISRN Oncol.  https://doi.org/10.1155/2013/290568 Google Scholar
  21. 21.
    McCarthy AM, Barlow WE, Conant EF, Haas JS, Li CI, Sprague BL, Armstrong K (2018) Breast cancer with a poor prognosis diagnosed after screening mammography with negative results. JAMA Oncol 4:998–1001CrossRefGoogle Scholar
  22. 22.
    Lukong KE (2017) Understanding breast cancer—the long and winding road. BBA Clin 7:64–77CrossRefGoogle Scholar
  23. 23.
    Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC (2014) Past, present, and future challenges in breast cancer treatment. J Clin Oncol 32(19):1979CrossRefGoogle Scholar
  24. 24.
    Espina C, McKenzie F, dos-Santos-Silva I (2017) Delayed presentation and diagnosis of breast cancer in African women: a systematic review. Ann EpidemiolGoogle Scholar
  25. 25.
    Soysal SD, Tzankov A, Muenst SE (2015) Role of the tumor microenvironment in breast cancer. Pathobiology 82(3–4):142–152CrossRefGoogle Scholar
  26. 26.
    Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K (2017) Role of tumor microenvironment in tumorigenesis. J Cancer 8(5):761CrossRefGoogle Scholar
  27. 27.
    Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, Mayordomo C, Ametller E, Mancino M, Gonzalez-Farre X, Russnes H (2013) Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res.  https://doi.org/10.1158/0008-5472.CAN-12-4573 Google Scholar
  28. 28.
    Singh D, Joshi DD, Hameed M, Qian J, Gascón P, Maloof PB, Mosenthal A, Rameshwar P (2000) Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc Natl Acad Sci 97(1):388–393CrossRefGoogle Scholar
  29. 29.
    Ni T, Liu Y, Peng Y, Li M, Fang Y, Yao M (2016) Substance P induces inflammatory responses involving NF-κB in genetically diabetic mice skin fibroblasts co-cultured with macrophages. Am J Transl Res 8(5):2179Google Scholar
  30. 30.
    Sio SW, Ang SF, Lu J, Moochhala S, Bhatia M (2010) Substance p upregulates cyclooxygenase-2 and prostaglandin E metabolite by activating ERK1/2 and NF-κB in a mouse model of burn-induced remote Acute lung injury. J Immunol.  https://doi.org/10.4049/jimmunol.1001739 Google Scholar
  31. 31.
    Marriott I, Mason MJ, Elhofy A, Bost KL (2000) Substance P activates NF-κB independent of elevations in intracellular calcium in murine macrophages and dendritic cells. J Neuroimmunol 102(2):163–171CrossRefGoogle Scholar
  32. 32.
    Simeonidis S, Castagliuolo I, Pan A, Liu J, Wang C-C, Mykoniatis A, Pasha A, Valenick L, Sougioultzis S, Zhao D (2003) Regulation of the NK-1 receptor gene expression in human macrophage cells via an NF-κB site on its promoter. Proc Natl Acad Sci 100(5):2957–2962CrossRefGoogle Scholar
  33. 33.
    Reddy BY, Greco SJ, Patel PS, Trzaska KA, Rameshwar P (2009) RE-1–silencing transcription factor shows tumor-suppressor functions and negatively regulates the oncogenic TAC1 in breast cancer cells. Proc Natl Acad Sci.  https://doi.org/10.1073/pnas.0809130106 Google Scholar
  34. 34.
    Greco SJ, Smirnov SV, Murthy RG, Rameshwar P (2007) Synergy between the RE-1 silencer of transcription and NFκB in the repression of the neurotransmitter gene TAC1 in human mesenchymal stem cells. J Biol Chem 282(41):30039–30050CrossRefGoogle Scholar
  35. 35.
    Morrison WB (2012) Inflammation and cancer: a comparative view. J Vet Intern Med 26(1):18–31CrossRefGoogle Scholar
  36. 36.
    O’Connor TM, O’Connell J, O’Brien DI, Goode T, Bredin CP, Shanahan F (2004) The role of substance P in inflammatory disease. J Cell Physiol 201(2):167–180CrossRefGoogle Scholar
  37. 37.
    Mayordomo C, García-Recio S, Ametller E, Fernández-Nogueira P, Pastor-Arroyo EM, Vinyals L, Casas I, Gascón P, Almendro V (2012) Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2. J Cell Physiol 227(4):1358–1366CrossRefGoogle Scholar
  38. 38.
    Campbell DE, Raftery N, Tustin R, Tustin NB, DeSilvio ML, Cnaan A, Aye PP, Lackner AA, Douglas SD (2006) Measurement of plasma-derived substance P: biological, methodological, and statistical considerations. Clin Vaccine Immunol 13(11):1197–1203CrossRefGoogle Scholar
  39. 39.
    Corbally N, Powell D, Tipton KF (1990) The binding of endogenous and exogenous substance-P in human plasma. Biochem Pharmacol 39(7):1161–1166CrossRefGoogle Scholar
  40. 40.
    Munoz M, Rosso M, Covenas R (2011) The NK-1 receptor: a new target in cancer therapy. Curr Drug Targets 12(6):909–921CrossRefGoogle Scholar
  41. 41.
    Brener S, González-Moles MA, Tostes D, Esteban F, Gil-Montoya JA, Ruiz-Avila I, Bravo M, Munoz M (2009) A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma. Anticancer Res 29(6):2323–2329Google Scholar
  42. 42.
    Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV, Muñoz M (2008) The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumor Biol 29(4):245–254CrossRefGoogle Scholar
  43. 43.
    Moles MG, Mosqueda-Taylor A, Esteban F, Gil-Montoya J, Díaz-Franco M, Delgado M, Muñoz M (2008) Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours. Oral Oncol 44(12):1127–1133CrossRefGoogle Scholar
  44. 44.
    Garcia-Recio S, Gascón P (2015) Biological and pharmacological aspects of the NK1-receptor. BioMed Res Int.  https://doi.org/10.1155/2015/495704 Google Scholar
  45. 45.
    Bowden JJ, Garland AM, Baluk P, Lefevre P, Grady EF, Vigna SR, Bunnett NW, McDonald DM (1994) Direct observation of substance P-induced internalization of neurokinin 1 (NK1) receptors at sites of inflammation. Proc Natl Acad Sci 91(19):8964–8968CrossRefGoogle Scholar
  46. 46.
    Douglas SD, Leeman SE (2011) Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann NY Acad Sci 1217(1):83–95CrossRefGoogle Scholar
  47. 47.
    Muñoz M, Rosso M, Carranza A, Coveñas R (2017) Increased nuclear localization of substance P in human gastric tumor cells. Acta Histochem 119(3):337–342CrossRefGoogle Scholar
  48. 48.
    Esteban F, Gonzalez-Moles MA, Castro D, Del Mar Martin-Jaen M, Redondo M, Ruiz-Avila I, Muñoz M (2009) Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology 54(2):258–260CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Surgical Oncology Research CenterMashhad University of Medical SciencesMashhadIran
  2. 2.Department of Clinical Biochemistry, Faculty of MedicineMashhad University of Medical SciencesMashhadIran
  3. 3.Department of Pathology, Faculty of MedicineMashhad University of Medical SciencesMashhadIran

Personalised recommendations